Howard M Katzenstein1, Wayne L Furman2, Marcio H Malogolowkin3, Mark D Krailo4, M Beth McCarville5, Alexander J Towbin6, Greg M Tiao7, Milton J Finegold8, Sarangarajan Ranganathan9, Stephen P Dunn10, Max R Langham11, Eugene D McGahren12, Carlos Rodriguez-Galindo13, Rebecka L Meyers14. 1. Division of Pediatric Hematology/Oncology, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, Tennessee. 2. Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee. 3. Division of Pediatric Hematology/Oncology, University of California at Davis Comprehensive Cancer Center, Sacramento, California. 4. Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California. 5. Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 7. Division of General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 8. Department of Pathology, Baylor College of Medicine, Houston, Texas. 9. Department of Pathology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 10. Department of Surgery, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware. 11. Division of Pediatric Surgery, St Jude Children's Research Hospital, Memphis, Tennessee. 12. Division of Pediatric Surgery, University of Virginia Children's Hospital, Charlottesville, Virginia. 13. Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee. 14. Department of Pediatric Surgery, Primary Children's Medical Center, Salt Lake City, Utah.
Abstract
BACKGROUND: The identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma. METHODS: Patients with newly diagnosed metastatic hepatoblastoma or those with a serum α-fetoprotein (AFP) level <100 ng/mL were eligible. Patients received 2 cycles of V at a dose of 1.5 mg/m2 /day intravenously on days 1 and 8 and I at a dose of 50 mg/m2 /day intravenously on days 1 to 5. Patients were defined as responders if they had either a 30% decrease in tumor burden according to Response Evaluation Criteria In Solid Tumors (RECIST) or a 90% (>1 log10 ) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5-fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone. RESULTS: A total of 32 patients with a median age at diagnosis of 26 months (range, 11-159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng/mL (85% of the initial AFP). The 3-year event-free and overall survival rates were 49% (95% confidence interval, 30%-65%) and 62% (95% confidence interval, 42%-77%), respectively. CONCLUSIONS: The VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined. Cancer 2017;123:2360-2367.
BACKGROUND: The identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma. METHODS:Patients with newly diagnosed metastatic hepatoblastoma or those with a serum α-fetoprotein (AFP) level <100 ng/mL were eligible. Patients received 2 cycles of V at a dose of 1.5 mg/m2 /day intravenously on days 1 and 8 and I at a dose of 50 mg/m2 /day intravenously on days 1 to 5. Patients were defined as responders if they had either a 30% decrease in tumor burden according to Response Evaluation Criteria In Solid Tumors (RECIST) or a 90% (>1 log10 ) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5-fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone. RESULTS: A total of 32 patients with a median age at diagnosis of 26 months (range, 11-159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng/mL (85% of the initial AFP). The 3-year event-free and overall survival rates were 49% (95% confidence interval, 30%-65%) and 62% (95% confidence interval, 42%-77%), respectively. CONCLUSIONS: The VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined. Cancer 2017;123:2360-2367.
Authors: Howard M Katzenstein; Cynthia Rigsby; Peter H Shaw; Torrey L Mitchell; Paul R Haut; Morris Kletzel Journal: J Pediatr Hematol Oncol Date: 2002-12 Impact factor: 1.289
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Daniël C Aronson; J Marco Schnater; Chris R Staalman; Gerrit J Weverling; Jack Plaschkes; Giorgio Perilongo; Julia Brown; Angela Phillips; Jean-Bernard Otte; Piotr Czauderna; Gordon MacKinlay; Anton Vos Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: J A Ortega; M D Krailo; J E Haas; D R King; A R Ablin; J J Quinn; J Feusner; J R Campbell; D A Lloyd; J Cherlow Journal: J Clin Oncol Date: 1991-12 Impact factor: 44.544
Authors: M K Ma; W C Zamboni; K M Radomski; W L Furman; V M Santana; P J Houghton; S K Hanna; A K Smith; C F Stewart Journal: Clin Cancer Res Date: 2000-03 Impact factor: 12.531
Authors: Rachel Purcell; Margaret Childs; Rudolf Maibach; Carina Miles; Clinton Turner; Arthur Zimmermann; Piotra Czauderna; Michael Sullivan Journal: Eur J Cancer Date: 2011-11-30 Impact factor: 9.162
Authors: Orren Beaty; Stacey Berg; Susan Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter C Adamson Journal: Pediatr Blood Cancer Date: 2010-09 Impact factor: 3.167
Authors: Maretta De Ioris; Laurence Brugieres; Arthur Zimmermann; Jean Keeling; Penelope Brock; Rudolf Maibach; Jon Pritchard; Liz Shafford; Joszef Zsiros; Piotr Czaudzerna; Giorgio Perilongo Journal: Eur J Cancer Date: 2007-12-31 Impact factor: 9.162
Authors: József Zsíros; Laurence Brugières; Penelope Brock; Derek Roebuck; Rudolf Maibach; Margaret Child; Bruce Morland; Michela Casanova; Daniele Pariente; Claudia Paris; Beatriz de Camargo; Milind Ronghe; Arthur Zimmermann; Jack Plaschkes; Piotr Czauderna; Giorgio Perilongo Journal: Eur J Cancer Date: 2012-07-24 Impact factor: 9.162
Authors: Rebecka L Meyers; Jon R Rowland; Mark Krailo; Zhengjia Chen; Howard M Katzenstein; Marcio H Malogolowkin Journal: Pediatr Blood Cancer Date: 2009-12 Impact factor: 3.167
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Howard M Katzenstein; Marcio H Malogolowkin; Mark D Krailo; Jin Piao; Alexander J Towbin; M Beth McCarville; Gregory M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; Milton J Finegold; Sarangarajan Ranganathan; Christopher B Weldon; Patrick A Thompson; Angela D Trobaugh-Lotrario; Allison F O'Neill; Wayne L Furman; Nadia Chung; Jessica Randazzo; Carlos Rodriguez-Galindo; Rebecka L Meyers Journal: Cancer Date: 2021-11-11 Impact factor: 6.921
Authors: Allison F O'Neill; Alexander J Towbin; Mark D Krailo; Caihong Xia; Yun Gao; M Beth McCarville; Rebecka L Meyers; Eugene D McGahren; Greg M Tiao; Stephen P Dunn; Max R Langham; Christopher B Weldon; Milton J Finegold; Sarangarajan Ranganathan; Wayne L Furman; Marcio Malogolowkin; Carlos Rodriguez-Galindo; Howard M Katzenstein Journal: J Clin Oncol Date: 2017-09-11 Impact factor: 44.544
Authors: Rosa Nguyen; M Beth McCarville; April Sykes; Shenghua Mao; Jianrong Wu; Max R Langham; Wayne L Furman Journal: Int J Clin Oncol Date: 2018-05-09 Impact factor: 3.402
Authors: James A Saltsman; William J Hammond; Nicole J C Narayan; David Requena; Helmuth Gehart; Gadi Lalazar; Michael P LaQuaglia; Hans Clevers; Sanford Simon Journal: Cancers (Basel) Date: 2020-09-18 Impact factor: 6.639